Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: A Trial of Neuroprotection With ACTH in Acute Optic Neuritis [Phase 4]
Phase 4 clinical trial update on neuroprotection with ACTH in acute optic neuritis for multiple sclerosis, terminated.
-
FDA approval · 2023-04-19FDA Approved: DALFAMPRIDINE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for dalfampridine submitted by Actavis Pharma, Inc., resulting in an updated regulatory action for t…
-
FDA approval · 2023-04-11FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)
FDA approved Biogen's supplemental application for TYSABRI (natalizumab). The action updates the product labeling to reflect the requested c…
-
FDA approval · 2023-04-11FDA Approved: DALFAMPRIDINE — Supplemental Application (Micro Labs Limited)
The FDA approved a supplemental application for dalfampridine from Micro Labs Limited.
-
CLINICAL_TRIALS trial_result · 2023-03-29Clinical Trial Update: National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis [Phase 3]
Phase 3 trial comparing sequential mitoxantrone and interferon versus interferon alone in patients with high progression risk in early multi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Minocycline in MS: Confirmation of Benefit [Phase 3]
Phase 3 trial investigating minocycline for multiple sclerosis and clinically isolated syndrome; the study is terminated after completion.
-
CLINICAL_TRIALS trial_result · 2023-03-22Clinical Trial Update: A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period [Phase 3]
Phase 3 extension study evaluating long-term safety of teriflunomide 14 mg daily in patients with a first clinical episode suggestive of mul…
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients [Phase 2]
Phase 2 clinical trial investigating repurposing metformin to improve therapeutic outcomes in patients with multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome [Phase 3]
A Phase 3 randomized, double-blind trial evaluating teriflunomide in radiologically isolated syndrome for multiple sclerosis.
-
FDA approval · 2023-03-16FDA Approved: TERIFLUNOMIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a teriflunomide generic product from Aurobindo Pharma Limited.
-
FDA approval · 2023-03-13FDA Approved: TERIFLUNOMIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved the original application for a generic version of teriflunomide.
-
FDA approval · 2023-03-13FDA Approved: TERIFLUNOMIDE — Original Application (Biocon Pharma Inc.)
FDA approved the original ANDA for teriflunomide from Biocon Pharma Inc., authorizing a generic version of the multiple sclerosis therapy.
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis [Phase 1, Phase 2]
Clinical trial update for intranasal insulin in multiple sclerosis across Phase 1 and Phase 2 has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-07Clinical Trial Update: Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis [Phase 2]
Phase 2 trial investigating belimumab added to B-cell depletion in relapsing-remitting multiple sclerosis was terminated with posted results…
-
CLINICAL_TRIALS trial_result · 2023-03-01Clinical Trial Update: Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis [Phase 2]
Phase 2 clinical trial on augmenting cerebral blood flow to treat established multiple sclerosis has been terminated; results posted in 2023…
-
FDA approval · 2023-02-22FDA Approved: BACLOFEN — Original Application (Nexus Pharmaceuticals LLC)
FDA approves Nexus Pharmaceuticals LLC's original ANDA for baclofen, a generic treatment for spasticity conditions.
-
CLINICAL_TRIALS trial_result · 2023-02-17Clinical Trial Update: Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis [Phase 2, Phase 3]
A completed Phase 2/3 clinical trial evaluating the efficacy and safety of BCD-033 and Rebif for multiple sclerosis has posted results.
-
FDA approval · 2023-02-10FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)
FDA approved a supplemental application for VUMERITY (diroximel fumarate) by Biogen Inc.
-
FDA approval · 2023-02-10FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
The FDA approved Biogen's supplemental application for Tecfidera (dimethyl fumarate), resulting in updated labeling for the drug.
-
FDA approval · 2023-01-31FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MAYZENT (siponimod) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: tDCS and Glucose Uptake in Leg Muscles [NA]
Clinical trial on transcranial direct current stimulation (tDCS) and glucose uptake in leg muscles for multiple sclerosis has completed with…
-
FDA approval · 2023-01-12FDA Approved: BAFIERTAM — Supplemental Application (Banner Life Sciences LLC)
The FDA approved a supplemental application for BAFIERTAM (monomethyl fumarate) submitted by Banner Life Sciences LLC.
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: Methylprednisolone During the Switch Between Natalizumab and Fingolimod [Phase 4]
Phase 4 clinical trial update on methylprednisolone during the switch from natalizumab to fingolimod in multiple sclerosis patients.
-
FDA approval · 2023-01-05FDA Approved: TERIFLUNOMIDE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark's supplemental application for teriflunomide, supporting a generic version of the multiple sclerosis therapy.
-
FDA approval · 2023-01-04FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
FDA indicates a supplemental application for COPAXONE (glatiramer acetate) by Teva Neuroscience, Inc. has been approved.